

INDGN/SE/2024-25/124

March 19, 2025

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
---	---

Dear Sir / Madam,

**Sub: Press Release – Indegene Expands Presence in Europe, Announces New Center in London**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, enclosed herewith is a press release dated March 19, 2025, titled 'Indegene Expands Presence in Europe, Announces New Center in London'.

The above information will be made available on the website of the Company: <https://www.indegene.com/>

This is for your information and records.

Yours sincerely,

**For Indegene Limited**

**Srishti Ramesh Kaushik**  
**Company Secretary and Compliance Officer**



Indegene Limited, Third Floor, Aspen G-4 Block,  
Manyata Embassy Business Park (SEZ), Outer Ring  
Road, Nagawara, Bengaluru- 560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777  
[www.indegene.com](http://www.indegene.com)

CIN: U73100KA1998PLC102040



Press Release

## Indegene Expands Presence in Europe, Announces New Center in London

**London, UK and Bengaluru, India, March 19, 2025:** Indegene, a digital-first life sciences commercialization company, today announced the launch of a new center in London. This aligns with the company's long-term growth strategy in Europe, reiterating its commitment to enable life sciences clients in the region to be future-ready.

Indegene's Europe-based clients can now benefit from this center as a strategic hub for consulting and commercialization solutions and modernize their operations with an AI-first approach. The company is strengthening its existing employee base in the region, with skillsets spanning a wide range of areas - consulting, creative, data and analytics, engineering and customer experience.

"London is a vital healthcare, technology and business innovation hub, with a great talent pool - making it an important market for life sciences companies in the region", said Manish Gupta, Chairman and CEO, Indegene. "With our new center, we are better positioned to dial up innovation and engagement with our clients here and help them holistically improve their commercialization processes with an AI-first approach and stay ahead of the curve."

Indegene [launched](#) a new entity in Spain last month. The company already has a significant presence in Europe, with centers in Germany, Ireland, and Switzerland. Last year, Indegene [acquired](#) Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities with teams spread across UK, Germany and US. In 2019, Indegene [acquired](#) DT Associates (now DT Consulting), a consulting services company in the UK that supports clients in the healthcare and life sciences space. The world's top 20 global biopharma companies, including many from Europe, trust Indegene for their commercialization needs.

### About Indegene

Indegene Limited (BSE: 544172, NSE: INDGN) is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient and modern way. Indegene brings together healthcare domain expertise, fit-for-purpose technology and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It's what drives Indegene's team and their purpose to enable healthcare organizations to be future-ready. To learn more, please visit [www.indegene.com](http://www.indegene.com)

For media inquiries, please contact: Yadunandan K V | [yadunandan.kv@indegene.com](mailto:yadunandan.kv@indegene.com)